LAS VEGAS, April 11, 2019 /PRNewswire/ -- Global spending on cancer therapies and supportive care drugs now exceeds USD 133 billion in 2017, and this amount is projected to reach USD 180-200 billion over the next five years.
About 4,000 patients are treated with Provenge each year in the US out of a possible 40,000 in 2018 currently. Out of three, Oncorine and Imlygic are the oncolytic virus-based gene therapies. Imlygic is the first oncolytic virus-based gene therapy to get approval in the US and Europe.
(Albany, US) DelveInsight launched Gene Therapy in Oncology - 2018
- Gene Therapy in Oncology report covers a descriptive account of its historical timeline & its evolution over the years, types, and vectors along with the corresponding gene-transfer methods.
- Gene Therapy in Oncology report incorporates cancer gene therapy products under development, showcasing their relative positioning in global Oncology therapeutic space.
- Gene Therapy in Oncology report includes a breakdown of pipeline products across different phases, emerging trends and comparative analysis of the products.
- Gene Therapy in Oncology report comprises comprehensive insight is provided into licensing & collaboration opportunities, deal values and funding details for emerging gene therapies
- Gene Therapy in Oncology report provides an edge while formulating business strategies and future developmental opportunities.
Click here to get a sample page : https://www.delveinsight.com/dev-sample.php?form_name=Gene-Therapy-in-Oncology:-Innovation-to-Commercialization,-Competitive-Landscape,-Technological-Advancements,-Market-Opportunities-&-Future-Directions
Almost, three decades after the first gene therapy trial, the approved gene therapies are only three in Europe and those are:-
- Glybera (alipogene tiparvovec)
- Imlygic (talimogene laherparepvec)
- Strimvelis (autologous CD34+ cells transduced to express ADA)
"Around 70% of the global clinical trials are running in the US, making it a most lucrative market for gene therapy in oncology."
The pipeline of gene therapy in cancer appears to be very strong with total of 47 products in development. Phase II & Phase I/II phase gene therapies grab 43% of the total clinical product share in 2018.
The company product analysis shows that majority of the products with the company have already made it to the clinical with around 64% of the products. Also, there are 36% products in Phase 1 ready, pre-clinical and discovery stages.
Overall in gene therapy oncology, around 23% of the products are partnered, and about 77% of products are non-partnered. The non-partnered products offer excellent investment opportunities for companies seeking a partnership in gene therapy in Oncology.
Click here to get a free demo : https://bit.ly/2I9Zo9L
Many companies that are exploring to kill the cancer cells efficiently are:-
- Dendreon Corporation
- Takara Bio
and many others
- Axalimogene filolisbac
and many others
Get a demo of the report:
Table of contents
1. Report Introduction
2. Executive Summary
3. Gene Therapy in Oncology Overview
4. Gene Therapy in Oncology Introduction
5. History- Evolution of Gene Therapy over the years
6. Gene Therapy in Oncology Role
7. Types of Gene Therapy
8. Gene Transfer- Types of Vectors and Gene Delivery Methods
9. Gene Therapy in Oncology Advantages
10. Key Challenges in Development of Gene Therapy for Oncology
11. Gene Editing in Gene Therapy
12. Types of Nucleases
13. Safety and Ethical Concerns
14. Companies developing Gene Editing Technologies
15. Regulatory Guidelines for Gene Therapy Products in 7MM
16. General Regulatory Environment
17. Regulatory Incentives and Support
18. Gene Therapy in Oncology Analysis –Innovation to Commercialization
19. Gene Therapy in Oncology Analysis by Total Products
20. Gene Therapy in Oncology Clinical Pipeline Analysis by Region
21. Gene Therapy in Oncology Pipeline Analysis by Regulatory Designations
22. Gene Therapy in Oncology Analysis by Companies Collaborations
23. Gene Therapy in Oncology Analysis by Product Type Development
24. Gene Therapy in Oncology Analysis by Product Type -Combination Therapy
25. Gene Therapy in Oncology Analysis by Originator
26. Gene Therapy in Oncology Analysis by Pharmaceutical Companies
27. Gene Therapy in Oncology Analysis by Technology
28. Gene Therapy in Oncology Analysis by Gene Therapy Targets
29. Gene Therapy in Oncology Analysis by Gene Therapy Vectors
30. Gene Therapy in Oncology Analysis by Gene Therapy Viral Vectors
31. Gene Therapy in Oncology Analysis by Gene Therapy Non-Viral Vectors
32. Marketed Gene Therapies
33. Provenge: Dendreon Corporation (acquired by San Power Group)
34. Gene Therapy in Oncology Marketed Products Sales Analysis
35. Gene Therapy in Oncology Marketed Products-Comparative Sales
36. Gene Therapies in Pipeline
38. Reimbursement Scenario for Cancer Gene Therapies in 7MM
39. The United States
40. EU-5 Countries
41. Market Access and Reimbursement Scenario for Cancer Gene Therapy in Japan
42. Cost Analysis of Gene Therapies- Challenges and Countermeasures
43. Hurdles in Approval and Revenue Generation
45. Evidence Generation
46. Valuation and Pricing
48. Gene Therapy in Oncology Future
49. DelveInsight Competitive Matrix Modeling
50. Market Drivers
51. Market Barriers
53. Report Methodology
54. DelveInsight Competitive Matrix
55. DelveInsight Capabilities
57. About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Journey from Target to T Cell Product: A Platform to identify Opportunities and Overcome Challenges, 2019- The Report provides in-depth analysis on the CAR-T cell profiles covering pre-clinical and clinical studies, Collaborations details and Deal values, Technologies and Targeted antigens, Investments and fundings. The Report provides the CAR-T licensing opportunities, acquisitions, market drivers and barriers followed by cost-analysis and SWOT Analysis. The report also covers the KOL views on CAR-T Therapy. Additionally, the report includes a comparative analysis of the sales of two approved drugs (Kymriah and Yescarta).
SOURCE DelveInsight Business Research, LLP